Overall verdict
Buy
6.7/10
1-year performance
+25.62%
Score breakdown
Up 25.6% over 1 year, 80% of the 52-week range.
Strongest: Shareholder return 7.6/10. Weakest: Growth 3.6/10.
22 analysts, target +0.1% vs the price.
Elevance Health, Inc., together with its subsidiaries, operates as a health benefits company in the United States. The company operates in four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to individual, employer group risk-based and fee-based, BlueCard, Medicare, Medicaid, and FEP members ; health products ; a broad array of fee-based administrative managed care services ;
and specialty and other insurance products and services, such as stop loss, dental, vision, and supplemental health insurance benefits. The company also operates in the pharmacy services business ; and markets and offers pharmacy services, including home delivery and specialty pharmacies, claims adjudication, formulary management, pharmacy networks, rebate administration, a prescription drug database, and member services, as well as infusion services and injectable therapies through ambulatory infusion centers.
In addition, it provides healthcare related services and capabilities, including specialty care enablement and utilization management support for specialized clinical domains ; behavioral health and comprehensive care management services ; palliative care services and management ; virtual care ; and payment integrity, subrogation, clinical data exchange through its HealthOS platform, research and data, reporting and clinical analytics, information technology, and business process support services, as well as manages home health, post-acute institutional management, and durable medical equipment costs ;
and supports plans in managing home and community-based services. The company provides its services under the Anthem Blue Cross and Blue Shield, Wellpoint, and Carelon brands. The company was formerly known as Anthem, Inc. and changed its name to Elevance Health, Inc. in June 2022. Elevance Health, Inc. was incorporated in 2001 and is based in Indianapolis, Indiana.
Sector
Health Care
Industry
Health Care Providers and Services
Primary listing
Nyse
United States
CEO
Gail Boudreaux
Founded
2001
Employees
97 100
Revenue / employee
2.1M USD
Next earnings
October 14, 2026 (estimated)
Institutional holders
- BlackRock, Inc.8.86%
- VANGUARD CAPITAL MANAGEMENT LLC6.56%
- STATE STREET CORP4.86%
- WELLINGTON MANAGEMENT GROUP LLP4.30%
- VANGUARD PORTFOLIO MANAGEMENT LLC2.90%
- Sanders Capital, LLC2.72%
- GEODE CAPITAL MANAGEMENT, LLC2.41%
- HARRIS ASSOCIATES L P2.30%
- Artisan Partners Limited Partnership2.14%
- Other institutions55.58%
- Rest of the register7.38%
1605 13F filings as of June 30, 2026: US managers above $100M, filed up to 45 days after quarter end. No insiders, no retail. A share on loan is declared by its lender and by whoever bought it from the short seller, so the total can exceed 100%.
Research uses the underlying stock’s market history. The purchase quote is calculated separately when you review your order.
52-week high
436.24 USD
52-week low
274.84 USD
1-year performance
25.62%
Rising
Year-to-date performance
13.63%
Rising
Drawdown
-7.56%
Mild pullback
Position in the 52-week range
80% of range
Against the world ETF
Over 17 years, from September 2009 to August 2026, the share did not do better than the world ETF once risk is accounted for. It earned more, but shaking 2.2 times harder: for the risk taken, the ETF paid better.
10,000 € placed at the end of September 2009 are worth today
| Elevance Health | 131 736 € |
| World ETF | 74 620 € |
| S&P 500 | 123 025 € |
| Risk-free placement | 11 288 € |
The risk
- Shaking:the share moves 2.2 times as much as the world ETF.
- Worst fall:-56 % between October 2022 and July 2025. 10,000 € placed at the top fell to 4 432 €. The world ETF, at worst: -34 %. The share has not returned to its high yet.
Elevance Health earned more than the world ETF since 2009
Value of 10,000 euros placed at the end of September 2009, dividends reinvested, in euros
- Elevance Health: 131 736 €
- World ETF: 74 620 €
- S&P 500: 123 025 €
- Risk-free placement: 11 288 €
Based on past performance. This is not a recommendation.
Range: 393.00 USD - 492.00 USD (3 methods agree)
The price implies growth of 0.07% per year; the company grows at 6.99%.
Gross margin 89.1%, net margin 2.5%, ROIC 6.7%, ROE 11.2%.
Net margin
2.47%
Exceptional
Sector 0.88%|S&P 12.97%
Gross margin
89.13%
Exceptional
Return on equity (ROE)
11.20%
High
Sector 8.69%|S&P 16.52%
Return on invested capital (ROIC)
6.73%
Fair
Free cash flow margin (FCF)
3.13%
Fair
Profit-to-cash conversion (FCF conversion)
1.27x
Fair
Margin stability
0.5 pts
Very steady
Revenue to net income
Growth
3.6/10Revenue up 1.4% over 1 year, 10.3% a year over 5, EPS 7.0% a year over 5.
Revenue (trailing 12 months)
201Md USD
Revenue growth (1y)
1.40%
Moderate
Revenue growth (3y)
27.16%
Solid
EPS growth (1y)
-13.02%
Declining
EPS CAGR (5y)
6.99%
Low
EPS revisions (3 months)
0.98%
Revised up
Valuation
6.7/10P/E 17.9x, forward P/E 19.5x, PEG 2.56. The multiple sits in the 33th percentile of its own 5-year history.
P/E (TTM)
17.9x
Cheap
Sector 30.1x|S&P 23.0x
Forward P/E
19.5x
Fair
EV / EBITDA
—
Sector 15.4x|S&P 14.5x
PEG
2.56
Very expensive
Sector 0.23|S&P 0.86
Fair value (reverse DCF)
430.61 USD
Fairly priced
P/E vs its own 5-year history
among the 33% lowest valuations
Cheaper than usual
Market cap
86.4Md USD
Financial strength
5.9/10Cash covers 33.0% of the debt, gearing 46.2%.
Net debt / EBITDA
—
Gearing (net debt / equity)
46.23%
Solid
Cash
10.2Md USD
Cash / market cap
11.84%
Solid
Cash / total debt
32.96%
Solid
Interest coverage
3.8x
Tight
Net debt
20.8Md USD
Equity
45.0Md USD
Closed daily candles, 2 years
Last close on September 24, 2026: 398.25 USD
- MM20406.97
- MM50396.21
- MM200364.51
- RSI 1445.0
Top panel: closed candles, 20, 50 and 200-day moving averages, with volume in grey. Bottom panel: 14-day RSI with dashed 30 and 70 levels.
200-day average slope, 1 month
+2.39%
200-day average slope, 3 months
+6.35%
50-day average slope, 1 month
+0.38%
Price structure
higher-low
Bullish RSI divergence
No
20-day volatility
1.68 % per day
Volatility change
-14.29%
Forecasts by fiscal year
| Fiscal year | EPS | Normalised EPS | Revenue | EBITDA | Net income |
|---|---|---|---|---|---|
| 2026 | 20.72 (7) | 27.17 (22) | 196 566 (13) | 10 410 (6) | 4 532 (7) |
| 2027 | 27.68 (6) | 29.54 (22) | 200 325 (13) | 10 620 (7) | 5 963 (7) |
Amounts in millions of USD, EPS in USD per share. In brackets, the number of analysts. Consensus as of September 24, 2026.
Same sub-industry: 10 companies behind the medians.
| # | Company | Code | Country | Overall / 10 | Fundamentals / 10 | Mkt cap | P/E | Net margin | Revenue growth | ROIC | Net debt / EBITDA | FCF yield | 1-year perf. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | PGNY | 7.5 | 7.8 | 2.0Md USD | 28.1x | 6.0 % | 5.3 % | 15.5 % | -3.1x | 9.0 % | 20.2 % | ||
| 2 | SAUD3 | 7.4 | 6.5 | 8.0Md USD | 14.3x | 10.6 % | 1213.1 % | 10.4 % | -0.3x | 1.6 % | 5.3 % | ||
| 3 | UNH | 7.4 | 6.7 | 333Md USD | 23.9x | 3.1 % | 0.4 % | 8.4 % | 1.9x | 7.1 % | 7.1 % | ||
| 4 | HQY | 7.0 | 6.4 | 7.5Md USD | 32.6x | 17.4 % | 7.6 % | 7.7 % | 1.4x | 6.5 % | -5.7 % | ||
| 5 | ELV | 6.7 | 6.0 | 86.4Md USD | 17.9x | 2.5 % | 1.4 % | 6.7 % | — | 7.3 % | 25.6 % | ||
| 6 | CNC | 5.9 | 4.9 | 30.7Md USD | Not meaningful (loss) | -2.5 % | 9.9 % | -12.2 % | 1.5x | 29.2 % | 89.2 % | ||
| 7 | HUM | 5.8 | 4.6 | 45.0Md USD | 35.5x | 0.9 % | 26.2 % | 4.1 % | -1.9x | 4.3 % | 47.6 % | ||
| 8 | CLOV | 4.8 | 3.8 | 2.4Md USD | Not meaningful (loss) | -0.7 % | 55.6 % | -5.1 % | 3.5x | 3.1 % | 38.3 % | ||
| 9 | MOH | 4.6 | 2.9 | 9.9Md USD | Not meaningful (loss) | -0.0 % | -4.8 % | -0.1 % | -20.7x | 2.7 % | 6.0 % |
